Ripple Science Corporation

Ripple Science Corporation specializes in patient engagement software that enhances recruitment and retention in clinical research, providing tailored management and communication tools for research teams. Ripple Science Corporation, founded in 2016 in Ann Arbor, US, focuses on developing software solutions for the clinical research sector. The company has raised a total of USD 2. 50 mn in funding, with the latest Seed round on January 7, 2020, attracting investors like Dundee Venture Capital and M25 Group.

The founders include Jacob Bonenberger and Nestor Lopez-Duran, with Peter Falzon serving as CEO. Ripple Science offers a comprehensive patient engagement software designed to enhance recruitment and retention in clinical research. Its platform includes adaptive study management tools, searchable registries for patient recruitment, real-time trial progress tracking, and tailored automation. This software is employed by academic research institutions, contract research organizations, and clinical settings in North America and Europe, helping resolve challenges related to patient engagement.

Ripple Science generates revenue primarily through subscription-based transactions for its patient engagement software, establishing contracts with research institutions and clinical organizations. While specific pricing is proprietary, engagements typically involve tiered subscription plans based on the clients' research requirements, fostering long-term relationships with research teams seeking to enhance trial efficiency and patient outcomes. Ripple Science intends to leverage its recent Seed funding of USD 2. 50 mn raised in January 2020 to expand its product offerings and strengthen its market presence.

Upcoming developments may include new features aimed at optimizing patient engagement and streamlining research processes. The company is also planning to enter new markets across North America and Europe by 2023, targeting academic institutions and clinical organizations to broaden its client base and enhance its impact in the clinical research field.